Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies.
about
The use of novel diagnostics to individualize immunosuppression following transplantationPreeclampsia from a renal point of view: Insides into disease models, biomarkers and therapy.What's new in clinical solid organ transplantation by 2013.Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection.Recent advances in renal transplantation: antibody-mediated rejection takes center stageUtility of HLA Antibody Testing in Kidney Transplantation.De novo development of antibodies to kidney-associated self-antigens angiotensin II receptor type I, collagen IV, and fibronectin occurs at early time points after kidney transplantation in children.Clinical relevance of preformed IgG and IgM antibodies against donor endothelial progenitor cells in recipients of living donor kidney grafts.The impact of angiotensin II type 1 receptor antibodies on post-heart transplantation outcome in Heart Mate II bridged recipients.Endothelial Cells in Antibody-Mediated Rejection of Kidney Transplantation: Pathogenesis Mechanisms and Therapeutic Implications.Analysis of Sera of Recipients with Allograft Rejection Indicates That Keratin 1 Is the Target of Anti-Endothelial Antibodies.Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms.Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection.Antibody-incompatible kidney transplantation in 2015 and beyond.Angiotensin II type 1 receptor antibodies in childhood kidney transplantation.The importance of non-HLA antibodies in transplantation.Susceptibility and progression of end stage renal disease are not associated with angiotensin II type 1 receptor gene polymorphism.Anti-angiotensin II type 1 receptor autoantibodies (AT1R-AAs) in patients with systemic sclerosis: lack of association with disease manifestations.Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection.Immune monitoring as prerequisite for transplantation tolerance trials.Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies.AST Cutting Edge of Transplantation 2013 Meeting Report: a comprehensive look at B cells and antibodies in transplantation.Proposed Diagnostic Criteria for Chronic Antibody-Mediated Rejection in Liver Allografts.Acute T cell-mediated rejection accompanied by C4d-negative acute antibody-mediated rejection and cell debris in tubulus: A case report.Role of alloimmunity and autoimmunity in allograft rejection.The Presence of Anti-Angiotensin II Type-1 Receptor Antibodies Adversely Affect Kidney Graft Outcomes.Renal allograft rejection: pieces of the puzzle.Angiotensin II Type 1 receptor antibodies: great expectations?Development of immune response to tissue-restricted self-antigens in simultaneous kidney-pancreas transplant recipients with acute rejection.Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation.Accelerated rejection, thrombosis, and graft failure with angiotensin II type 1 receptor antibodies.C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies.Is pre-transplant sensitization against angiotensin II type 1 receptor still a risk factor of graft and patient outcome in kidney transplantation in the anti-HLA Luminex era? A retrospective study.Acute kidney transplant rejection mediated by angiotensin II type 1 receptor antibodies in a pediatric hyperimmune patient.Endothelial precursor cell cross-match using Tie-2-enriched spleen cells.Patient Engagement in Kidney Research: Opportunities and Challenges Ahead.Bortezomib in ABO-incompatible kidney transplant desensitization: a case report.Post-Transplant Natural Antibodies Associate with Kidney Allograft Injury and Reduced Long-Term Survival.Short- and long-term effects of the use of RAAS blockers immediately after renal transplantation.The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation.
P2860
Q26864686-2F01E18E-E9C4-4820-A577-9B5669BFE08AQ34453242-C7D24D54-0864-4218-9174-0D6541FCD964Q34761349-427B915C-2691-47C8-B856-A421D1E06E9FQ35332030-7E3D3C21-4D65-49CA-A051-9BF0F2CA40E8Q35659332-5C4851F0-DEC7-4AA9-B43D-5652AB47E841Q35790601-C3F3730A-77C6-49F7-98A4-F5B90DBF8687Q35798183-D380CB1C-084F-407F-8AF9-4E58A4738F6BQ35832457-8DF9AA21-18FB-40EB-BAB5-EB3E20CDF3FCQ37179122-1E8AC3AB-FEE5-4C33-A0F4-BBEF81A31726Q37642331-86992F29-8354-469E-84F2-83514694072DQ37654350-7AA8EAC8-07FC-45E5-A5AF-3C27CBDBFE57Q38169496-A4BD2200-3E62-45C1-8C21-7EA7F1671ABFQ38282840-42B53849-E71B-4504-851D-6F3F5C993FAAQ38286995-FE27C980-8FB8-4BB6-965F-E0005353D6A1Q38859507-EB7A2FDB-859C-45A7-9CF5-BD2B44497650Q38877375-F2E2F638-CAD2-413F-B518-40574A95F0C5Q39044820-28FE557D-4832-45D5-A701-F6C3FCC318B2Q39076219-645962B5-B5C8-4C92-81EB-9FCB0F569041Q39217968-4294EC0D-928C-48F5-AB5A-A710CBDBB2CFQ39314792-BBB8C07B-4445-491F-A745-64FC30678789Q39737548-D82E85AD-BD82-4EB8-9BA2-5AD6CB882275Q40331013-D583D7AE-7A2E-4B63-9B44-A74E04E8D37FQ40429580-403AC86D-589E-4E8C-8BA2-C2A1F2041675Q41192310-0D5C182A-1AE6-432A-A174-0114488B282EQ41226453-C1DE085C-8754-41B8-8FA7-B770A9B09DCAQ42233729-85047390-078C-4A03-8579-A99C4187969EQ42582852-20D6FD2B-39E8-4AD0-AFA9-631D62588A8CQ44855309-F8808D51-067E-4EDB-9577-CD280A5630B6Q45982490-22F720CD-476F-45B6-A8BE-EE3B2ADD41DBQ46409439-9FB05A27-061A-4ACE-A6E5-32C249B62137Q46456694-D4ED81BF-F3E6-437C-99CB-5FBAC7E05919Q47571875-E0F2121F-1EC7-43F4-B6ED-369B9C6C8451Q48160896-63E0AB9B-DAA5-44ED-A530-18A868B700F9Q48295872-5B61D963-B1E2-4A0E-B748-A3F5485BE9ACQ48324851-6D5E269B-7694-437E-80D1-748566AC632FQ49378996-DB2D11C7-F356-48E0-9607-0F3F7C2333CFQ50996014-12767B7E-646D-4A57-9265-C0011E1FF9D5Q52618068-C06BB49C-8030-4D58-A327-B0A092F8B76BQ53096709-FC486BF3-A23A-4B72-876D-957008DC982EQ53186858-35E59C03-1CCB-4D78-8E5B-79B14647D7B8
P2860
Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Higher risk of kidney graft fa ...... II type-1 receptor antibodies.
@en
Higher risk of kidney graft fa ...... II type-1 receptor antibodies.
@nl
type
label
Higher risk of kidney graft fa ...... II type-1 receptor antibodies.
@en
Higher risk of kidney graft fa ...... II type-1 receptor antibodies.
@nl
prefLabel
Higher risk of kidney graft fa ...... II type-1 receptor antibodies.
@en
Higher risk of kidney graft fa ...... II type-1 receptor antibodies.
@nl
P2093
P2860
P356
P1476
Higher risk of kidney graft fa ...... II type-1 receptor antibodies.
@en
P2093
C E Haisch
J Hopfield
K P Briley
L M Rebellato
M Taniguchi
P G Catrou
P I Terasaki
P2860
P304
P356
10.1111/AJT.12395
P407
P577
2013-08-13T00:00:00Z